Perceptive Advisors’s Alder Biopharmaceuticals ALDR Stock Holding History

Perceptive Advisors’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-384,169	Closed	-$7.99M	–	182
2017 Q1	$7.99M	Hold	384,169	–	–	0.46%	48
2016 Q4	$7.99M	Sell	384,169 -7,111	-2%	-$185K	0.57%	46
2016 Q3	$12.8M	Sell	391,280 -8,720	-2%	-$266K	0.83%	29
2016 Q2	$9.99M	Buy	400,000 +25,000	+7%	+$676K	0.69%	33
2016 Q1	$9.18M	Buy	+375,000	New	+$8.68M	0.81%	30
2015 Q2	–	Sell	-150,000	Closed	-$4.33M	–	198
2015 Q1	$4.33M	Buy	+150,000	New	+$4.12M	0.34%	56

Other funds holding ALDR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Perceptive Advisors's ALDR Position: Q2 2017 in Review

Perceptive Advisors sold out of Alder Biopharmaceuticals (ALDR) in Q2 2017, closing a stake of 384,169 shares — an estimated $7.99M sold.

Perceptive Advisors first reported a position in ALDR in Q1 2015 and held it in 6 quarters. The position peaked at $12.8M in Q3 2016. 128 funds tracked by Wall St. Rank hold ALDR as of Q2 2017.

Perceptive Advisors reported no remaining Alder Biopharmaceuticals position as of Q2 2017 after selling out during the quarter.
Perceptive Advisors sold 384,169 Alder Biopharmaceuticals shares in Q2 2017, an estimated $7.99M.
Perceptive Advisors first reported a position in Alder Biopharmaceuticals in Q1 2015 and held it in 6 quarters.
Perceptive Advisors's Alder Biopharmaceuticals position peaked at $12.8M in Q3 2016.
128 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2017.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.